Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Women of childbearing potential not using a medically acceptable means of contraception. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
798c0983-5265-47ea-bfcd-735738793482 | Histologic Documentation of invasive breast cancer by core needle or incisional biopsy. Excess baseline biopsy tumor tissue sufficient to make three 5-micron sections must be available for molecular analyses as part of this study. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | The invasive cancer must be estrogen receptor alpha (ER)-positive, with ER staining present in greater than 50% staining of invasive cancer cells by IHC. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | The invasive cancer must be human epidermal growth factor receptor 2 (HER2) negative (IHC 0-1+, or with a fluorescence in situ hybridization (FISH) ratio of <1.8 if IHC is 2+ or if IHC has not been done). A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | Clinical stage I-III invasive breast cancer with the intent to treat with surgical resection of the primary tumor. Tumor must be 2cm to provide adequate tissue. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | Patients with multi-centric or bilateral disease are eligible if the target lesions meet the other eligibility criteria. Samples from all available tumors are requested for research purposes. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | Women age 18, for whom adjuvant treatment with an aromatase inhibitor would be clinically indicated. Women must be either post-menopausal, or pre-menopausal having undergone oophorectomy. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | Patients must meet the following clinical laboratory criteria: A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | Absolute neutrophil count (ANC) 1000/mm3 and platelet count 75,000/mm3. Total bilirubin 1.5 X the upper limit of normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 x ULN. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | - Ability to give informed consent. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | Prior endocrine therapy for any histologically confirmed cancer is not allowed. Prior endocrine therapy that was administered 5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowed. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | Systemic drug treatment to induce ovarian suppression if woman is pre-menopausal. A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
798c0983-5265-47ea-bfcd-735738793482 | Any other neoadjuvant therapy for breast cancer (i.e., treatment with any other anti-cancer agent besides Letrozole (10-21)days before surgical resection of the primary tumor). A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Intervention secondary trial: Arm I (Web-Based CPM-DA) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Intervention secondary trial: Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Intervention secondary trial: Internet-Based Intervention: Receive web-based CPM-DA Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Intervention secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Intervention secondary trial: Arm II (Usual Care) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Intervention secondary trial: Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Intervention secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness secondary trial: Arm I (Web-Based CPM-DA) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness secondary trial: Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness secondary trial: Internet-Based Intervention: Receive web-based CPM-DA Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness secondary trial: Arm II (Usual Care) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness secondary trial: Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts secondary trial: Arm I (Web-Based CPM-DA) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts secondary trial: Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts secondary trial: Internet-Based Intervention: Receive web-based CPM-DA Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts secondary trial: Arm II (Usual Care) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts secondary trial: Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Text message management prompts secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control secondary trial: Arm I (Web-Based CPM-DA) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control secondary trial: Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control secondary trial: Internet-Based Intervention: Receive web-based CPM-DA Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control secondary trial: Arm II (Usual Care) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control secondary trial: Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness secondary trial: Arm I (Web-Based CPM-DA) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness secondary trial: Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness secondary trial: Internet-Based Intervention: Receive web-based CPM-DA Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness secondary trial: Arm II (Usual Care) Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness secondary trial: Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM. Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
127e9179-6781-4b9a-abe9-080d2ffad591 | primary trial: Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness secondary trial: Survey Administration: Ancillary studies Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: female patients 18-70 years of age; secondary trial: Age 52-75 years old; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: female patients 18-70 years of age; secondary trial: Identification as Latina/Hispanic/Chicana female; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: female patients 18-70 years of age; secondary trial: Residence in Pilsen, Little Village, East Side or South Chicago; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: female patients 18-70 years of age; secondary trial: No history of health volunteerism; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: female patients 18-70 years of age; secondary trial: No history of breast cancer; and Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: female patients 18-70 years of age; secondary trial: Lack of a mammogram within the last two years Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: female patients 18-70 years of age; secondary trial: Not meeting all inclusion criteria; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: female patients 18-70 years of age; secondary trial: Women will be excluded if they participated in formative focus groups Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: adenocarcinoma of the breast; secondary trial: Age 52-75 years old; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: adenocarcinoma of the breast; secondary trial: Identification as Latina/Hispanic/Chicana female; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: adenocarcinoma of the breast; secondary trial: Residence in Pilsen, Little Village, East Side or South Chicago; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: adenocarcinoma of the breast; secondary trial: No history of health volunteerism; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: adenocarcinoma of the breast; secondary trial: No history of breast cancer; and Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: adenocarcinoma of the breast; secondary trial: Lack of a mammogram within the last two years Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: adenocarcinoma of the breast; secondary trial: Not meeting all inclusion criteria; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: adenocarcinoma of the breast; secondary trial: Women will be excluded if they participated in formative focus groups Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous invasive breast cancer if diagnosed >5 years before entering study; secondary trial: Age 52-75 years old; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous invasive breast cancer if diagnosed >5 years before entering study; secondary trial: Identification as Latina/Hispanic/Chicana female; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |